BEDFORD, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience ...

Posterior and/or peripheral anterior synechia Figure 16, iris atrophy, cataract due to inflammation and/or medication and secondary glaucoma may develop.

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -27.59% and 37.36%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

The presence of posterior synechia at the time that uveitis is diagnosed in children with juvenile idiopathic arthritis-associated uveitis may be a risk factor in the development of early cataract ...

Ocular Therapeutix obtained FDA support to use the phase 3 SOL-R trial as the next step in the regulatory process for Axpaxli, according to a press release.

Swan 7 also had the rare opportunity to study the ocular changes of an embryo obtained shortly after the mother contracted rubella late in the second month of pregnancy.

The cause is believed to be capillary dropout in the retina. [77] The fibrous tissue that accompanies neovascularization may contract, causing ectropion uveae or peripheral anterior synechia. [78] ...

To investigate the effects of tropicamide and cyclopentolate, which are two anti-muscarinic agents commonly used in the ophthalmologic practice, on subfoveal choroidal choroidal thickness (ChT) in ...